Anchiano Therapeutics' stock set to close well below its IPO price
Shares of Anchiano Therapeutics Ltd. was on track to close below its initial public offering price (http://www.marketwatch.com/story/anchiano-therapeutics-ipo-prices-below-assumed-price-2019-02-12) on its debut, bucking the gains in its Nasdaq biotechnology peers and the broader stock market. The stock's first trade was at its IPO price of $11.50 at 10:02 a.m. Eastern, and that was the highest price it traded. The Israel-based biotechnology company's stock fell as much as 8.3% below its IPO price, at the intraday low of $10.55, but has pared some losses to be down 6.4% in recent trade. Meanwhile, the
-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
February 12, 2019 15:21 ET (20:21 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.